Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program

被引：0
|
作者：
Ho, Cheryl [1 ,2 ]
Lim, Howard J. [1 ,2 ]
Regier, Dean A. [3 ,4 ]
机构：
[1] BC Canc, Dept Med Oncol, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada
[2] Univ British Columbia, Dept Med, Vancouver, BC, Canada
[3] BC Canc, Canc Control Res, Vancouver, BC, Canada
[4] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada
来源：
JAMA NETWORK OPEN | 2021年 / 4卷 / 08期
关键词：
D O I：
10.1001/jamanetworkopen.2021.20301
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：4
相关论文
共 50 条
  • [1] FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment
    Ho, Cheryl
    Lim, Howard J. J.
    Regier, Dean A. A.
    [J]. CURRENT ONCOLOGY, 2022, 29 (02) : 402 - 410
  • [2] A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics A Review
    Beaver, Julia A.
    Howie, Lynn J.
    Pelosof, Lorraine
    Kim, Tamy
    Liu, Jinzhong
    Goldberg, Kirsten B.
    Sridhara, Rajeshwari
    Blumenthal, Gideon M.
    Farrell, Ann T.
    Keegan, Patricia
    Pazdur, Richard
    Kluetz, Paul G.
    [J]. JAMA ONCOLOGY, 2018, 4 (06) : 849 - 856
  • [3] US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018
    Omae, Kenji
    Onishi, Akira
    Sahker, Ethan
    Furukawa, Toshi A.
    [J]. JAMA NETWORK OPEN, 2022, 5 (09)
  • [4] Comparison of Oncology Drug Approval Between Health Canada and the US Food and Drug Administration
    Ezeife, Doreen A.
    Truong, Tony H.
    Heng, Daniel Y. C.
    Bourque, Sylvie
    Welch, Stephen A.
    Tang, Patricia A.
    [J]. CANCER, 2015, 121 (10) : 1688 - 1693
  • [5] Accelerated Approval of Oncology Products: The Food and Drug Administration Experience
    Johnson, John R.
    Ning, Yang-Min
    Farrell, Ann
    Justice, Robert
    Keegan, Patricia
    Pazdur, Richard
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (08) : 636 - 644
  • [6] Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
    Cherla, Avi
    Naci, Huseyin
    Kesselheim, Aaron S.
    Gyawali, Bishal
    Mossialos, Elias
    [J]. JAMA INTERNAL MEDICINE, 2021, 181 (04) : 490 - 498
  • [7] Product Approval and Public Health at the US Food and Drug Administration
    Lurie, Peter
    Sharfstein, Joshua M.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (24): : 2469 - 2470
  • [8] Oncology Drug Development and Approval of Systemic Anticancer Therapy by the US Food and Drug Administration
    Martell, Robert E.
    Sermer, David
    Getz, Kenneth
    Kaitin, Kenneth I.
    [J]. ONCOLOGIST, 2013, 18 (01): : 104 - 111
  • [9] Gleevec™ for the treatment of chronic myelogenous leukemia:: US food and drug administration regulatory mechanisms, accelerated approval, and orphan drug status
    Cohen, MH
    Moses, ML
    Pazdur, R
    [J]. ONCOLOGIST, 2002, 7 (05): : 390 - 392
  • [10] Reforming Reimbursement for the US Food and Drug Administration's Accelerated Approval Program to Support State Medicaid Programs
    Sachs, Rachel E.
    Donohue, Julie M.
    Dusetzina, Stacie B.
    [J]. JAMA HEALTH FORUM, 2022, 3 (11): : E224115
12345